Abstracts

SWITCHING TO A NRTI-FREE 2 DRUG REGIMEN (2DR) – A SUB-ANALYSIS OF THE DUALIS STUDY

Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir) demonstrated non-inferiority with regard to viral suppression in people living with HIV (PLWH) in the DUALIS study. This sub-analysis focuses on changes in metabolic and renal parameters when sparing the NRTI…

2DR VS 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY

Accumulating evidence suggests that integrase strand-transfer inhibitors (INSTI)-based initial antiretroviral therapy (ART) results in greater CD4/CD8 ratio recovery compared to other regimens. However, it is unknown whether the treatment initiation with INSTI-based two-drug regimens (2DR) has a different impact on the CD4/CD8 ratio recovery compared to INSTI-based 3DR. We emulated a target trial to assess…

SWITCHED VERSUS RECYCLED nRTIs IN PI-BASED SECOND-LINE REGIMENS IN EAST AFRICA

World Health Organization guidelines recommend switching nucleoside reverse transcriptase inhibitors (NRTIs) in second-line antiretroviral therapy (ART) after first-line failure. Recent clinical trial data suggest that recycling NRTIs in protease inhibitor (PI)-based second-line ART may have similar efficacy to switched NRTIs. We evaluate this question using programmatic data from East Africa. We analyzed data from the…

RESUPPRESSION AFTER VIROLOGICAL FAILURE IN DOLUTEGRAVIR AND EFAVIRENZ-BASED REGIMENS

Dolutegravir (DTG) and other integrase inhibitor (INSTI) based treatments are highly effective, tolerable, and have high barriers to genetic resistance. Participants who display virological rebound on DTG-based regimens may be able to re-suppress with adherence counselling, without the risk of developing resistance and preventing switches to less tolerable or more expensive alternatives. The following analysis…

MOLNUPIRAVIR INCREASES RANDOM SARS-CoV-2 RNA ERRORS WITHOUT SELECTION FOR RESISTANCE

Molnupiravir (MOV), the orally administered prodrug of the antiviral ribonucleoside analogue, N-hydroxycytidine (NHC) has received emergency use authorization for treatment of COVID-19. NHC inhibits viral replication by introduction of random transition errors across the viral genome, resulting in non-infectious virus. In the Phase 2/3 (MOVe-OUT) study, non-hospitalized participants received MOV or placebo (PBO) for 5…